GGrantIndex
← Leaderboards

Michael D. Taylor

University Of California, San Francisco

$7,522,868
Attributed
$19,240,147
Total exposure
5
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY201025
$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$19,240,147 · 5

By mechanism

R01$18,899,259 · 4
P50$340,888 · 1

Top collaborators

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorMedulloblastomaGenesIn VivoSubgroupShh GeneGeneticNeoplasm MetastasisMouse ModelPathway InteractionsCellsChildMalignant Neoplasm Of BrainSurvivorsPreventPrimary NeoplasmCerebrospinal FluidCandidate Disease GeneMalignant NeoplasmsNovel StrategiesBrain NeoplasmsMorbidity - Disease RateNovel TherapeuticsRecurrence

Grant awards (32)

Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$706,017
R01 · FY2025 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$630,753
R01 · FY2025 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$157,894
R01 · FY2025 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$749,215
R01 · FY2024 · CA
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$670,714
R01 · FY2024 · CA
Project 3: Exploit Immune Consequences of U1 Mutations in Sonic Hedgehog (Shh) Medulloblastoma$340,888
P50 · FY2024 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2023 · CA
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$706,017
R01 · FY2023 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2022 · CA
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$643,914
R01 · FY2022 · CA
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,563
R01 · FY2022 · NS
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$159,218
R01 · FY2022 · CA
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$819,398
R01 · FY2021 · CA
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2021 · CA
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,614
R01 · FY2021 · NS
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2020 · CA
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,684
R01 · FY2020 · NS
Mouse models to discover new drivers of medulloblastoma$724,440
R01 · FY2019 · CA
Prevention and treatment of lethal metastases in group 3 medulloblastoma$564,833
R01 · FY2019 · NS
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2018 · CA
Prevention and treatment of lethal metastases in group 3 medulloblastoma$578,681
R01 · FY2018 · NS
Mouse models to discover new drivers of medulloblastoma$794,344
R01 · FY2017 · CA
Cellular and Genetic Basis of Anaplastic Medulloblastoma$617,747
R01 · FY2015 · CA
Cellular and Genetic Basis of Anaplastic Medulloblastoma$599,474
R01 · FY2014 · CA
Medulloblastoma and Metastases$455,065
R01 · FY2014 · CA
Cellular and Genetic Basis of Anaplastic Medulloblastoma$581,217
R01 · FY2013 · CA
Medulloblastoma and Metastases$442,785
R01 · FY2013 · CA
Cellular and Genetic Basis of Anaplastic Medulloblastoma$618,678
R01 · FY2012 · CA
Medulloblastoma and Metastases$488,139
R01 · FY2012 · CA
Cellular and Genetic Basis of Anaplastic Medulloblastoma$640,572
R01 · FY2011 · CA
Medulloblastoma and Metastases$506,777
R01 · FY2011 · CA
Medulloblastoma and Metastases$557,223
R01 · FY2010 · CA